2.18
-0.1(-4.39%)
Currency In USD
| Previous Close | 2.28 |
| Open | 2.29 |
| Day High | 2.3 |
| Day Low | 2.15 |
| 52-Week High | 5.22 |
| 52-Week Low | 1 |
| Volume | 12,202 |
| Average Volume | 104,545 |
| Market Cap | 52.21M |
| PE | -0.83 |
| EPS | -2.64 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 2.2 |
| Change | -0.1 |
If you invested $1000 in Celularity Inc. (CELU) since IPO date, it would be worth $22.24 as of May 30, 2025 at a share price of $2.18. Whereas If you bought $1000 worth of Celularity Inc. (CELU) shares 4 years ago, it would be worth $22.04 as of May 30, 2025 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
GlobeNewswire Inc.
Apr 25, 2025 9:30 PM GMT
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain f
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
GlobeNewswire Inc.
Apr 14, 2025 12:00 PM GMT
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcersFLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CE
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
GlobeNewswire Inc.
Apr 07, 2025 12:00 PM GMT
Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseasesFLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative